Primary Series Hospitalization/Severe Disease ■ non-mRNA ■ Multiple mRNA Study Country Design VE (95% CI) С 0.95 (0.92, 0.97) Bar-On et al. (5) Israel Barda et al. (22) Israel MC 0.93 (0.88, 0.97) Muhsen et al. (69) С 0.93 (0.85, 0.97) Israel USA MC Sharma et al. (71) 0.45 (0.27, 0.58) Mattiuzzi and Lippi (37) Italy С 0.69 (0.56, 0.78) USA С 0.82 (0.56, 0.94) McConeghy et al. (57) (S1) С USA 0.46 (-0.16, 0.79) McConeghy et al. (57) (S2) Mehta et al. (82) USA MC 0.81 (0.80, 0.82) С USA Tartof et al. (19) 0.70 (0.48, 0.83) USA MC Butt et al. (20) 0.52 (0.46, 0.57) UK MC Hulme et al. (75) 0.80 (0.78, 0.82) 0.96 (0.88, 1.00) Andersson et al. (17) **Finland** MC \vdash MC 0.88 (0.71, 1.00) Andersson et al. (17) Norway Andersson et al. (17) MC 0.90 (0.80, 1.00) Sweden Andersson et al. (17) Sweden MC 0.88 (0.81, 0.95) USA MC \vdash 0.53 (0.48, 0.58) Ioannou et al. (39) С Singapore Ng et al. (76) 0.70 (0.49, 0.82) С Kislaya et al. (31) (60-79yo) Portugal 0.21 (0.02, 0.36) С Portugal Kislaya et al. (31) (80+yo) 0.16 (0.01, 0.28) Ridgway et al. (29) USA MCC \vdash 0.59 (0.54, 0.63) USA MC Desai et al. (18) 0.44 (0.02, 0.68) Chemaitelly et al. (78) MC 0.80 (0.56, 0.91) Qatar -0.250 0.25 0.5 0.75 1 Vaccine Effectiveness (VE)

Mortality

